6th Webinar: IASLC Grand Rounds Series- Biomarkers and Personalized Medicine for Patients with Lung Cancer
The Sixth webinar in the series: IASLC Grand Rounds Series - Biomarkers and Personalized Medicine for Patients with Lung Cancer took place June 23, 2014 at 8:00PM EDT.
|Keith Kerr, BSc, MB, ChB, FRC Path, FRCPE
Honorary Chair in Pulmonary Pathology
University of Aberdeen
Ramaswamy Govindan, MD - Program Chair
The IASLC Lung Cancer Grand Rounds Webinar Series continues on June 23, 2014 as Professor Keith Kerr will focus on developments in personalized medicine for patients with lung cancer, the impact that this has had, and could have in the future, for those patients, and how the pursuit of biomarkers to predict response to targeted therapy has changed lung cancer diagnostics. This has implications not only for surgical pathologists and molecular pathologists but also for oncologists and any specialist involved in obtaining tissue for lung cancer diagnosis. The presentation will briefly discuss the diagnostic approach to lung cancer samples with relevance to personalized therapy, the status of EGFR and ALK testing, introduce the plethora a possible new biomarkers that may be required in the future, and discuss the practical implication of providing this service.
Following Prof. Kerr's presentation, there will be ample opportunity for Professor Kerr and Dr. Govindan to address questions and comments submitted by the audience via internet chat.
This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants. Participants who complete a pre-and post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar.
If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program.
This series is supported in part by unrestricted educational grants provided by Bristol-Myers Squibb Co., Celgene and Genentech